University of East Anglia
The University of East Anglia (UEA) was an important partner within our programme, particularly in applied and clinically oriented research. Over the lifetime of the programme, we awarded approximately £180,000 across eight grants, supporting a mix of treatment development, early clinical evaluation, and doctoral training.
A significant strand of our funding at UEA was directed towards eye disease, including research into cataract treatment, posterior capsular opacification and secondary visual loss following surgery. Several of these projects progressed into Phase I clinical development, reflecting the applied nature of the work and UEA’s strength in translating research questions into early clinical studies. We supported both the development of new treatment approaches and the evaluation of existing ones, including drug‑based interventions.
Cancer research also featured within our UEA portfolio. We funded work on leukaemia and melanoma, largely through PhD studentships and early‑stage research projects. These awards supported exploratory investigation rather than full translational programmes, and we viewed them as contributing to skills development and knowledge generation rather than guaranteed downstream outcomes.
In addition to specific projects, we supported consumables and doctoral training that helped sustain research momentum during critical phases. These smaller, practical grants played an important role in enabling ongoing work to continue, particularly where other funding sources were limited or transitional.
UEA’s portfolio stood out for its balance between laboratory research and clinical relevance. While not as large in scale as our funding at institutions such as Nottingham or Bristol, the UEA grants were notable for their clarity of purpose and proximity to patient benefit, especially in ophthalmology.
In retrospect, our funding at the University of East Anglia illustrated how medium‑sized, well‑targeted investments could support applied research with clear clinical trajectories. It complemented our larger, more discovery‑focused investments elsewhere and contributed to the overall diversity and balance of the closed programme.
